Novo Nordisk (0QIU) Gets a Buy from J.P. Morgan
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout
Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...
STAT7h
The biotech updates you need to read this morning
Pfizer suffered a blow earlier this month when new data showed that its gene therapy for Duchenne muscular dystrophy failed ...
The Financial Express7h
Novo Nordisk’s oral diabetes drug reduces heart-related risks by 14 percent
Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the ...
Catalent’s Maselli to continue as CEO post Novo Holdings deal close
Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to ...
STAT10h
Catalent tries to reassure customers about its deal with Novo Holdings
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...